15, October, 2025
# Sign In
  1. Home
  2. Market Highlights

Market Highlights

Get the latest Indian stock / share market highlights, BSE/NSE stock news, business research reports & details - updated daily by Money Times.

April 24, 2025

  • Daily Morning Report – Date: 24.04.2025
  • NIFTY OUTLOOK: 24328.95 FII: 3332.93 cr DII: -1234.46 cr
  • As discussed yesterday, market behaviour followed expected lines as strong bullish momentum led the Nifty to rally up to our resistance at 24353, with an intraday high of 24359.30.
  • A bearish Hanging Man candlestick pattern appeared on the daily chart after a sharp rally, indicating possible resistance and rising selling pressure. If selling persists and Nifty breaks below 24240 decisively, it may slip to 24153–24065, and further to 23977 if sustained.
  • Despite positive sentiment, any upmove from current levels may face resistance at 24425–24505. A breakout and sustained move above this zone could push Nifty toward 24593–24683.
  • Bank Nifty OUTLOOK:
  • SPOT: 55370.05 PCR: 1.00 Max CE OI at 56000 & Max PE OI at 55000
  • On 23rd April 2025, Bank Nifty closed at 55370.05, down 0.50% from the previous day. The index moved 936.20 points during the session, with an intraday high of 56098.70 and a low of 55162.50.
  • The previous day's high of 56098.70 and low of 55162.50 can be considered as today’s resistance and support, respectively.
  • Technical View on Daily Chart:
  • The key technical levels on the daily chart of Bank Nifty are 56278 as resistance and 54900 as support. Yesterday, the index opened near the resistance level and some selling pressure was observed. If the index crosses the minor resistance of 55689 today, it may retest 56278. On the downside, if it breaches the support of 54900, it could slide towards 53960.
  • The Relative Strength Index (RSI) for Bank Nifty is at 73.9, indicating an overbought zone. Some profit booking may occur as levels above 70 are considered overbought.
  • Bank Nifty Day SMA Analysis:
  • Bank Nifty is trading above all 8 SMAs (5, 10, 20, 30, 50, 100, 150, 200-day).
  • It is trading below none of the SMAs.
  • One bearish candlestick pattern was identified in Bank Nifty.
  • • Bearish Engulfing
  • Macros:
  • 1. Dollar index @ 99.385
  • 2. Vix @ 28.45 ( -6.93 % )
  • 3. Crude @ 66.14
  • 4. 10 years bond yield @ 4.358
  • Note: The US administration has signaled a de-escalation in the trade war with China. Besant stated that the current tariffs—145% on Chinese products and 125% on US products—are not sustainable. He added that these tariffs would need to come down for trade talks to proceed, but Trump is unlikely to act unilaterally.
  • The apparent softening of the US stance is a positive sign for markets shaken by erratic trade policies. However, it remains important to watch how China responds, especially since it has not reacted to recent tariff hikes.
  • Conclusion: De-escalation is a welcome move for global economies, as China is a key manufacturing hub. If a deal is reached, we may see a rebound in the dollar index and a drop in bond yields.
  • Contributed by
  • Ashok bhandari : INH000019549
  • -------------------------------------xxxxxxx-------------------------------------------------------------------xxxxxxx---------------------------------
  • US tariffs likely to hit India's growth directly by as much as 0.5% points, says FinMin Secy
  • Source: The Economic Times
  • https://search.app/cJBx9
  • Shared via the Google App
  • Samsung considering India smartphone shift as Trump tariff squeezes Vietnam exports
  • Source: Moneycontrol
  • https://search.app/eDBFw
  • *Bajaj Housing Finance Q4 FY25 Highlights*
  • - AUM up 26% YoY to ₹1.14L Cr
  • - Net Profit jumps 54% YoY to ₹587 Cr
  • - Net Interest Income rises 31% YoY to ₹823 Cr
  • - ROA at 2.4% | ROE at 12.1%
  • - Strong growth momentum continues!
  • @beatthestreet10
  • RANE MADRAS: Co. Allots 1.13 Cr New Shares Post Amalgamation with Rane Engine Valve Limited ('REVL') and Rane Brake Lining Limited (`RBL')
  • Board approved allotment of 1,13,71,870 new equity shares to eligible shareholders of REVL and RBL.
  • New shares allotted as per approved share exchange ratio from the amalgamation scheme.
  • Issued equity capital increased to Rs. 27.64 Cr from Rs. 16.27 Cr.
  • @beatthestreet10
  • KESAR PETROPRODUCT ; Board Meet On 28 April To Consider Appointment of Mr. Shreyas Sharma as Chief Executive Officer (CEO) of the Company.
  • @beatthestreet10
  • INFOSYS: Infosys Sets Up Wholly-Owned Subsidiary in Australia
  • New entity Infosys Australia Technology Services Pty Ltd Incorporated on April 23, 2025, in Australia Operates in IT and IT-enabled services
  • 100% owned by Infosys Singapore Pte. Ltd., a subsidiary of Infosys
  • @beatthestreet10
  • WH Press Sec. Leavitt: Trump won't give up on fair trade practices. It's not fair to say Trump is softening.
  • Trump won't give up on fair trade practices. It's not fair to say Trump is softening.
  • There will be a fair trade deal with China. There will be no unilateral reduction on China tariff.
  • It's up to Trump what the China tariff rate will be.
  • @beatthestreet10
  • SHOPPERS STOP ; HDFC MF BOUGHT ADDITIONAL 2.2 % STAKE ON 22 APRIL VIA OPEN MARKET
  • STAKE INCREASED TO 7.47 % FROM EARLIER 5.27 %
  • @beatthestreet10
  • CITI ON DIVIS LABS
  • (CMP: ₹5,924.50)
  • MAINTAIN BUY
  • TARGET PRICE: ₹7,050
  • Divis has high potential to become primary supplier given capacity addition
  • Orforglipron, Eli Lilly's potential best-in-class oral GLP-1, is the next addition in DIVI's pipeline
  • Capacity: current 300 Mt+ planned intermediaries of capacity
  • Proposed capacity 18 MT+ Capacity for peptide GLP 1
  • Expect more round of capex with scale up in products
  • Have forecasted $ 800mn +GLP1 revenues for Divis by 2030 E
  • Divis is the top pharma pick
  • @beatthestreet10
  • SYNGENE Q4 HIGHLIGHTS
  • CEO Says Syngene’s Q4 revenue rose 11% YoY, crossing Rs 1,000 Cr for the first time; EBITDA grew 9%.
  • Key highlight: acquisition of a biologics facility in the US, boosting its CDMO presence. Strong growth in biologics and discovery services aided performance.
  • FY25 growth at 4%, aligned with guidance, with H2 recovery after a weak first half.
  • @beatthestreet10
  • JPMORGAN ON TATA CONSUMER
  • Maintains 'Neutral' Rating & Hikes Target Price To ₹1,100 From ₹970
  • In-Line In Q4; Eyeing Double Digit Revenue Growth With Gradual Margin Revival
  • India Core: Tea Volume Normalises; Salt Does Well
  • Post The Recent Share Price Rally, Valuations Cap Upside
  • @beatthestreet10
  • Nomura on Anant Raj
  • Buy, TP cut to Rs 700 on reduced fund raising visibility
  • Still attractive despite a more conservative stance on data center segment
  • EPS CAGR of +40% over FY26-27F
  • DC capacity at 28MW IT load by 1QFY26F (vs 6MW currently)
  • Internal accruals to fund 50% of capex requirement; peak net/debt to equity under 0.5x if co goes through loan route (instead of QIP)
  • Robust residential launch pipeline for FY26F of 3.1msf with total GDV of RsR60bn
  • @beatthestreet10
  • PIRAMAL PHARMA
  • Arm Piramal Healthcare enters into stock subscription pact for PPL Pharma
  • Signs pact to buy preference shares worth Rs 1,626 crore
  • To convert outstanding $150 million loans owed by PPL Pharma
  • @beatthestreet10
  • Mining as a theme is coming up big
  • Deepak Fertilizer
  • Deepak Mining Solutions Limited, a wholly owned material subsidiary of the Company is issuing Compulsorily Convertible Debentures of Rs. 800 Crores to Tata Capital Limited (Investor 1 – Rs.500 Crores) and SCM Growth LLP (Investor 2 – Rs.300 Crores) on private placement basis
  • @beatthestreet10
  • CITI on Tata Cons
  • Buy, TP Rs 1325
  • 4Q In-line; Margin Recovery Likely In 2HFY26
  • Believe Co’s growth trajectory remains intact led by competitive performance in core segments (tea, salt) & strong growth in new categories
  • @beatthestreet10
  • JEFFERIES ON SIEMENS
  • Maintain Buy; target price Rs 3300
  • Demerged entity - pure T&D equipment play
  • Siemens demerged on 7 April 2025, and shares of Siemens Energy India were allotted to Siemens shareholders on 14 April
  • SE is likely to be listed in the next 10-70 days. On listing, SE should be India's largest pure play power T&D equipment player by market cap at USD8 bn+, as the next players are Hitachi and GE at less than $5-7 bn
  • Believe SE should see 40% EPS CAGR in FY24-27E, driven by the robust T&D opportunity pipeline and operating leverage
  • Siemens ex-energy still offers upside potential
  • @beatthestreet10
  • Nomura on Anant Raj
  • Buy, TP cut to Rs 700 on reduced fund raising visibility
  • Still attractive despite a more conservative stance on data center segment
  • EPS CAGR of +40% over FY26-27F
  • DC capacity at 28MW IT load by 1QFY26F (vs 6MW currently)
  • Internal accruals to fund 50% of capex requirement; peak net/debt to equity under 0.5x if co goes through loan route (instead of QIP)
  • Robust residential launch pipeline for FY26F of 3.1msf with total GDV of RsR60bn
  • @beatthestreet10
  • DALMIA BHARAT Q4 : UPDATES
  • Commissioned 2.9 MnT cement capacity in Assam and Bihar, raising total to 49.5 MnT.
  • Announced Rs 3,520 Cr investment for clinker and grinding units in Karnataka and Maharashtra to boost presence in southern and western markets.
  • Solar capacity at Lanka and group captive additions raised total operational RE to 267 MW, targeting 595 MW by FY26.
  • @beatthestreet10
  • MS on Dalmia Bharat
  • UW, TP Rs 1650
  • 4Q: Slightly weaker than expected
  • Net rev 6% below MSe
  • Vols weaker, down 3% YoY vs. MSe at +3% YoY
  • Realizations also weaker than expected; seems weak pricing trends in southern region weighed on overall blended pricing
  • @beatthestreet10
  • NUVAMA ON LTIMINDTREE
  • Maintain Buy, target price cut to Rs 5200 vs Rs 5350
  • LTIMindtree reported weak Q4FY25 results
  • BFSI and manufacturing sustain momentum; margins soft
  • LTIM had a challenging FY25 as growth slowed down in H2FY25 due to a delay in deal execution and client-specific challenges
  • CEO-designate Venu Lambu has highlighted his strategic priority to deliver industry-leading growth as well as improve margins from Q1FY26
  • Headwinds receding; key strategic initiatives by CEO-designate
  • Are trimming FY26E/27E EPS (-3.3%/-2.5%) due to slightly lower growth and margin expectations
  • Continue to value LTIM at 25x FY27PE
  • Incoming CEO to strengthen operations
  • @beatthestreet10
  • HSBC on Bajaj Hsg Fin
  • Reduce, TP Rs 100
  • 4Q: AUM growth healthy; high-cost ratio & yield compression due to competition was drag
  • Expect EPS growth to slow due to pressure on AUM growth, NIM compression & normalisation of credit costs
  • Cut FY26-27 EPS est by 2.8-3.1%
  • @beatthestreet10
  • NUVAMA ON TATA CONSUMER
  • Retain Buy, target price hiked to Rs 1335 from Rs 1255
  • Marginally cutting FY26E/27E EPS by 1.3%/1.7%
  • Revenue in-line with estimates, EBITDA beat
  • 2% uptick in India tea volumes below est, salt 5% in-line
  • Coffee prices remain elevated with average prices for Robusta/Arabica surging 97%/65% YoY
  • @beatthestreet10
  • PERSISTENT SYSTEMS : Persistent Systems Approves Merger of Subsidiary Arrka Infosec
  • Board approves merger of wholly owned subsidiary Arrka Infosec with Persistent Systems
  • Aimed at rationalization and operational efficiency within the group
  • Merger to proceed via NCLT route, subject to statutory approvals
  • No cash or share consideration involved; related party norms not applicable
  • @beatthestreet10
  • SUN PHARMACEUTICAL; Sun Pharma, Moebius Publish Key Data on Non-Opioid Osteoarthritis Therapy MM-II
  • Two peer-reviewed articles highlight MM-II's clinical efficacy and unique cartilage-protective action
  • Phase 2b trial shows single injection offers 26-week pain relief with good safety
  • MM-II gains US FDA Fast Track status; Sun Pharma to present new data at OARSI 2025
  • MM-II targets $2B global knee osteoarthritis market with non-opioid alternative therapy
  • @beatthestreet10
  • SYNGENE Q4 ; FY26 GUIDANCE
  • REVENUE; Syngene has guided for FY26 revenue growth of mid-single-digits (base biz growth of early teens to be offset by inventory destocking likely in Librela).
  • EBITDA GUIDANCE; New biologics facility ramp-up will raise costs and depreciation, leading to EBITDA margin moderation to mid-20s and a YoY decline in PAT. ( FY25 Margin At 29 % )
  • Also Fy25 EBITDA Margins AT 29 % V 30 % GUIDANCE
  • Analyst Says FY26 guidance significantly below expectations, likely 25% Ebitda cuts for FY26
  • @beatthestreet10
  • UBS India Strategy
  • Upgrade India to Neutral from Underweight; still prefer China over India
  • Expect 8% upside in NIFTY 50; one year target of 26,000
  • Key Buys are Hindustan Unilever, ICICI Bank, Indigo, Sun Pharma, Trent, TVS Motors
  • Key Sells are Asian Paints, Bajaj Finance, Cummins India and Jubilant Foodworks
  • @beatthestreet10
  • CAN FIN Q4 HIGHLIGHTS
  • NIM at 4qtr high of 3.82% vs 3.73%QOQ
  • Disbursements at Rs2455cr, up 6.1%YOY & 30.65%QOQ
  • AUM at Rs38217 cr, up 9.2%YOY & 2.9%QOQ
  • ROA at 2.59% vs 2.28% YOY & vs 2.25% QOQ
  • ROE at 18.5% vs 17.3% YOY & vs 17.55% QOQ
  • GNPA ratio at 0.87% vs 0.92%QOQ
  • @beatthestreet10
  • THYROCARE TECH Q4 HIGHLIGHTS
  • Consolidated revenue increased by 21% year-over-year (YoY) with Pathology and Radiology segments growing by 23% YoY and 7% YoY respectively
  • Total volume in FY25 grew to 167.9 million, largest by far on volume
  • Revenue from franchise surged by 22% YoY, and partnership revenue saw 24% YoY growth
  • Q4 Consolidated gross margin stood at 74% v 70 % YOY, and normalized EBITDA margin was 35% V 24 % YOY
  • Opened new labs in Bhagalpur and Kashmir
  • @beatthestreet10
  • Zomato : CEO Rakesh Ranjan is stepping down amid a market share decline in company’s core segment.
  • Deepinder to manage the company until a permanent replacement is finalised.
  • Please note Eternal is the parent company of Zomato.
  • @beatthestreet10
  • Persistent Systems – Q4 Financials (QOQ):
  • Net Profit: ₹396 Cr vs ₹373 Cr
  • Revenue: ₹3,240 Cr vs ₹3,060 Cr
  • EBIT: ₹505 Cr vs ₹465 Cr
  • EBIT Margin: 15.58% vs 14.88%
  • @beatthestreet10
  • PITTI ENG Q4 CONCALL
  • GUIDANCE; Targeting a revenue growth of 15% for Fy26
  • Company anticipates a 75 BPS to 1% increase in EBITDA margins over the next 12-18 months
  • For FY26, the company is targeting ₹2,000 crores with a volume of around 68,000 tons
  • For Fy27, with a peak capacity of 72,000 tons, revenue is expected to be around ₹2100-2200 crores
  • @beatthestreet10
  • Q???????????????????????????????? ???????????????????????????? ????????????????????!
  • ????????????????: 24 Apr, 2025
  • ????????????????????????????????????:
  • - Bhansali Engineering Polymers Ltd
  • - Titan Company Ltd
  • - Hindustan Unilever Ltd
  • - Nestle India Ltd
  • - Supreme Industries Ltd
  • - Emmessar Biotech & Nutrition Ltd
  • - Mphasis Ltd
  • - Cyient Ltd
  • - Axis Bank Ltd
  • - Tanla Platforms Ltd
  • - Persistent Systems Ltd
  • - Ashoka Buildcon Ltd
  • - Adani Energy Solutions Ltd
  • - L&T Technology Services Ltd
  • - Laurus Labs Ltd
  • - SBI Life Insurance Company Ltd
  • - Indian Energy Exchange Ltd
  • - AAVAS Financiers Ltd
  • - Sterling & Wilson Renewable Energy Ltd
  • - SBI Cards & Payment Services Ltd
  • - Macrotech Developers Ltd
  • - Jayshree Chemicals Ltd
  • - New Markets Advisory Ltd
  • - Kretto Syscon Ltd
  • - Waaree Technologies Ltd
  • - Forbes Precision Tools & (https://t.me/BeatTheStreet10) Machine Parts Ltd
  • - Artson Engineering Ltd
  • - Sahaj Solar Ltd
  • - Sudarshan Pharma Industries Ltd
  • TG: https://t.me/BeatTheStreet10
  • SAMHI partners with GIC for $300mn upscale hotel investment platform, including five key assets worth INR 2200 Cr.
  • https://t.me/BeatTheStreet10
  • GIC to acquire 35% in SAMHI subsidiaries; INR 2200 Cr valuation; US$300M growth investment planned
  • https://t.me/BeatTheStreet10
  • GIC invests Rs. 752 Cr for 35% stake in SAMHI JV, reducing debt and boosting PAT by 15-20%.
  • @beatthestreet10
  • BAJAJ FINANCE + 3 % ON BONUS , STOCK SPLIT BOARD MEET
  • @beatthestreet10
Panchkarma